U.S. flag

An official website of the United States government

NM_000747.3(CHRNB1):c.53C>G (p.Ala18Gly) AND Congenital myasthenic syndrome 2A

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Sep 22, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000690025.7

Allele description [Variation Report for NM_000747.3(CHRNB1):c.53C>G (p.Ala18Gly)]

NM_000747.3(CHRNB1):c.53C>G (p.Ala18Gly)

Genes:
LOC130060147:ATAC-STARR-seq lymphoblastoid silent region 8121 [Gene]
CHRNB1:cholinergic receptor nicotinic beta 1 subunit [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
17p13.1
Genomic location:
Preferred name:
NM_000747.3(CHRNB1):c.53C>G (p.Ala18Gly)
HGVS:
  • NC_000017.11:g.7445180C>G
  • NG_008026.1:g.5094C>G
  • NM_000747.3:c.53C>GMANE SELECT
  • NP_000738.2:p.Ala18Gly
  • NC_000017.10:g.7348499C>G
  • NM_000747.2:c.53C>G
Protein change:
A18G
Links:
dbSNP: rs534380483
NCBI 1000 Genomes Browser:
rs534380483
Molecular consequence:
  • NM_000747.3:c.53C>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Congenital myasthenic syndrome 2A
Synonyms:
Myasthenic syndrome, congenital, 2a, slow-channel
Identifiers:
MONDO: MONDO:0014581; MedGen: C4225374; Orphanet: 590; OMIM: 616313

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000817701Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Uncertain significance
(Sep 22, 2023)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group, Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV000817701.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

This sequence change replaces alanine, which is neutral and non-polar, with glycine, which is neutral and non-polar, at codon 18 of the CHRNB1 protein (p.Ala18Gly). This variant is present in population databases (rs534380483, gnomAD 0.2%). This variant has not been reported in the literature in individuals affected with CHRNB1-related conditions. ClinVar contains an entry for this variant (Variation ID: 569406). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024